|Articles|September 1, 2001

September 2001
Volume 7
Issue 9

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Author(s)A. Mark Fendrick, MD, Dean G. Smith, PhD, Michael E. Chernew, PhD

Download PDF: A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Articles in this issue

almost 25 years ago

Article

Effect of Moderate Weight Loss on Health-Related Quality of Life: An Analysis of Combined Data From 4 Randomized Trials of Sibutramine vs Placebo

almost 25 years ago

Article

A Randomized Intervention to Improve Ongoing Participation in Mammography

almost 25 years ago

Article

Impact of a Targeted Asthma Intervention Program on Treatment Costs in Patients with Asthma

almost 25 years ago

Article

Comparison of Prevalence, Cost, and Outcomes of a Combination of Salmeterol and Fluticasone Therapy to Common Asthma Treatments

almost 25 years ago

Article

Weight Loss and Health-Related Quality of Life

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

Articles in this issue

Related Content

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Trending on AJMC

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

ACA Enrollment Erosion Deepens After Open Enrollment Ends

What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO

Efgartigimod Effective in Broad Subsets of Patients With gMG

Alopecia Areata Takes a Hidden Toll on Work, Relationships, and Self-Care